Evidence map›Paper›PMID 41986737›Full record

ArticleNature medicine2026

Proteomic risk score for early prediction of kidney disease progression in individuals with APOL1 high-risk genotypes.

Chenyu Li, Shola M Richards, Ghazal Quinn, Amin Abedini, Minyan Zhu, Tanya Verma, Samer Mohandes, Rebecca Pitts, Vesna Barros, Xiazi Qiu and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Chenyu LiRenal, Electrolyte and Hypertension Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Shola M RichardsNovartis Biomedical Research, Novartis Campus, Basel, Switzerland.
Ghazal QuinnRenal, Electrolyte and Hypertension Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Amin AbediniRenal, Electrolyte and Hypertension Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-8875-0070
Minyan ZhuRenal, Electrolyte and Hypertension Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Tanya VermaRenal, Electrolyte and Hypertension Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Samer MohandesRenal, Electrolyte and Hypertension Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Rebecca PittsNovartis Biomedical Research, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-4733-414X
Vesna BarrosNovartis Biomedical Research, Novartis Campus, Basel, Switzerland.
Xiazi QiuNovartis Biomedical Research, Cambridge, MA, USA.
Taehwan ShinNovartis Biomedical Research, Cambridge, MA, USA.
Joseph J LoureiroNovartis Biomedical Research, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-7222-9160
Nancy FinkelNovartis Biomedical Research, Cambridge, MA, USA.
Aditya SurapaneniDivision of Precision Medicine, New York University School of Medicine, New York, NY, USA.
Josef CoreshDivision of Precision Medicine, New York University School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-4598-0669
Morgan E GramsDivision of Precision Medicine, New York University School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-4430-6023
Anil KarihalooCardiorenal Division, R&ED, Novo Nordisk, Malov, Denmark.
Hongzhe LiDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-3662-3907
Anurag VermaDivision of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-5063-9107
Marylyn RitchieDepartment of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-1208-1720
Daniel J RaderDepartment of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-9245-9876
Penn Medicine BioBank
William F DietrichNovartis Biomedical Research, Cambridge, MA, USA.
Lori L JenningsNovartis Biomedical Research, Cambridge, MA, USA.
Katalin SusztakRenal, Electrolyte and Hypertension Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ksusztak@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0002-1005-3726

Funding

Phenotypic Diversity in COVID-19UL1TR001878 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2016 to 2025
$102.4M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - COORDINATING CENTER - TASK AREA B.2 AND B.375N92022D00001 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID · 2022 to 2025
$13.7M
Role of the Notch Pathway in Kidney InjuryR01DK076077 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI KATALIN SUSZTAK · 2007 to 2026
$8.0M
Epigenetics of Chronic Kidney DiseaseR01DK087635 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI KATALIN SUSZTAK · 2009 to 2026
$7.0M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00003 · NHLBI · UNIVERSITY OF MINNESOTA · PI LUTSEY, PAMELA L. · 2022 to 2025
$5.1M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00005 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI WAGENKNECHT, LYNNE E · 2022 to 2025
$5.0M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00004 · NHLBI · UNIVERSITY OF MISSISSIPPI MED CTR · PI WINDHAM, BEVERLY GWEN · 2022 to 2025
$4.8M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00002 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI ARGANI, PEDRAM · 2022 to 2025
$4.7M
APOL1 associated kidney diseaseR01DK105821 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI SUSZTAK, KATALIN · 2016 to 2024
$4.6M
Integrative Omics, Chronic Kidney Disease, and Adverse Outcomes in Older AdultsR01DK124399 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI JOSEF CORESH, Morgan Erika Grams · 2020 to 2026
$3.6M
Profiling Cardiovascular Events and Biomarkers in the Very Old to Improve Personalized Approaches for the Prevention of Cardiac and Vascular DiseaseR01HL134320 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI BALLANTYNE, CHRISTIE MITCHELL, SELVIN, ELIZABETH · 2016 to 2019
$3.1M
NCATS NIH HHS UL1 TR001878NHLBI NIH HHS 75N92022D00001NHLBI NIH HHS 75N92022D00002NHLBI NIH HHS 75N92022D00003NHLBI NIH HHS 75N92022D00004NHLBI NIH HHS 75N92022D00005NHLBI NIH HHS R01 HL134320NIDDK NIH HHS R01 DK076077NIDDK NIH HHS R01 DK087635NIDDK NIH HHS R01 DK105821NIDDK NIH HHS R01 DK124399U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) R01 DK076077, R01 DK087635, and R01 DK105821
6 · The paper itself

Abstract

Individuals of African ancestry carrying APOL1 (apolipoprotein L1) high-risk genotypes face a markedly increased risk of kidney failure, yet tools to identify those individuals likely to progress to chronic kidney disease are lacking. Here we profiled plasma proteomes of 851 Penn Medicine BioBank participants of African ancestry (285 males and 566 females) with APOL1 high-risk genotypes and preserved estimated glomerular filtration rate (eGFR) (≥60 ml min

Indexed as

Apolipoprotein L1Kidney DiseasesProteomicsRenal Insufficiency, ChronicAgedBlack PeopleDisease ProgressionFemaleGenetic Predisposition to DiseaseGenetic Risk ScoreGenotypeGlomerular Filtration RateHumansMaleMiddle AgedRisk FactorsAPOL1 protein, humanApolipoprotein L1

Identifiers

PMID41986737
PMCPMC13190321

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.